PRESS RELEASES
2014

07.22.14 - MEDIA ADVISORY: GENSPERA'S G-202 HCC CLINICAL TRIAL PRESENTATION FROM
                    5TH ASIA-PACIFIC PRIMARY LIVER CANCER EXPERT (APPLE) MEETING AVAILABLE

07.15.14 – GENSPERA PRESENTS G-202 HCC CLINICAL TRIAL UPDATE AT 5TH ASIA-PACIFIC
                    PRIMARY LIVER CANCER EXPERT MEETING

07.14.14 – KAREG CORPORATION INITIATES COVERAGE ON GENSPERA WITH A SPECULATIVE
                    BUY RECOMMENDATION

07.07.14 – GENSPERA TO PRESENT ONGOING HCC TRIAL DATA AT APPLE 2014 CONGRESS
                    JULY 12TH IN TAIPEI

06.30.14 – MEDIA ADVISORY: GENSPERA 2014 BIO INTERNATIONAL PRESENTATION AVAILABLE

06.24.14 – GENSPERA RELEASES 2014 BIO INTERNATIONAL PRESENTATION AND HCC
                    CLINICAL TRIAL UPDATE FOR G-202

06.23.14 – GENSPERA, INC. (OTCQB: GNSZ) RELEASES UPDATED CORPORATE VIDEO:
                   “GENSPERA HAS TARGETED ITS ACTIVE INGREDIENT THAPSIGARGIN TO KILL
                   ONLY THE CELLS WE SELECT: CANCER”

06.19.14 – GENSPERA CEO, CRAIG DIONNE, TO PRESENT UPDATE ON LEAD DRUG CANDIDATE
                    G-202 AT 2014 BIO INTERNATIONAL CONVENTION

05.29.14 – GENSPERA ANNOUNCES $3.33 MILLION REGISTERED PUBLIC OFFERING

03.18.14 – FIRST PATIENT ENROLLED IN GENSPERA G-202 PHASE II GLIOBLASTOMA TRIAL

02.06.14 – GENSPERA CEO, CRAIG DIONNE, TO PRESENT AT BIO CEO & INVESTOR
                    CONFERENCE, FEBRUARY 10th

2013

10.28.13 – GENSPERA CEO TO PRESENT AT NEW YORK SOCIETY OF SECURITY ANALYSTS’
                    LIFE SCIENCES CONFERENCE

10.22.13 – FINAL PHASE I DATA ON GENSPERA’S G-202 PRESENTED AT SYMPOSIUM ON
                    MOLECULAR TARGETS AND CANCER THERAPEUTICS

10.17.13 - GENSPERA G-202 PRINCIPAL INVESTIGATOR PRESENTS PHASE I DATA
                    AT SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

08.19.13 - GENSPERA ANNOUNCES $5 MILLION IN PRIVATE FINANCING

06.06.13 - GENSPERA RECEIVES PATENT ON TARGETED PROSTATE CANCER DRUGS

04.10.13 - GENSPERA CHIEF EXECUTIVE OFFICER CRAIG DIONNE TO PRESENT TO BIO
                    BUSINESS FORUM™ ON APRIL 23, 2013 IN CHICAGO

03.14.13 - GENSPERA’S G-202 GRANTED U.S. ORPHAN DRUG DESIGNATION FOR TREATMENT
                    OF HEPATOCELLULAR CARCINOMA

02.21.13 - GENSPERA ANNOUNCES FIRST PATIENT TREATED IN G-202 PHASE II 
                    HEPATOCELLULAR CARCINOMA TRIAL

2012

11.27.12 - GENSPERA’S CEO TO PRESENT AT THE NYSSA LIFE SCIENCES CONFERENCE

11.09.12 - INTERIM DATA ON GENSPERA’S G-202 PRESENTED AT SYMPOSIUM ON
                   MOLECULAR TARGETS AND CANCER THERAPEUTICS

10.25.12 - GENSPERA /THE STATEWIDE CLINICAL TRIALS NETWORK OF TEXAS TO  CONDUCT                         PHASE II STUDY OF G-202 IN PATIENTS WITH HEPATOCELLULAR  CARCINOMA

08.31.12 - GENSPERA OBTAINS AUTHORIZATION FOR G-202 PHASE II TRIAL IN THE
                    UNITED KINGDOM

08.21.12 - GENSPERA APPOINTS NANCY JEAN BARNABEI VP FINANCE AND TREASURER

07.31.12 - GENSPERA CLEARED TO INITIATE PHASE II G-202 TRIAL IN PROSTATE CANCER

06.28.12 - GENSPERA G-202 DATA IN PEER-REVIEWED JOURNAL SUPPORTS
                    PRODRUG STRATEGY

05.31.12 - GENSPERA APPOINTS DR. PETER E. GREBOW TO ITS BOARD OF DIRECTORS

03.28.12 - GENSPERA'S G-202 CLINICAL TRIAL ADVANCES TO PHASE Ib COMPANY
                    PREPARES TO LAUNCH PHASE II

2011

06.29.11 - GENSPERA ENTERS AGREEMENT WITH UNIVERSITY OF COPENHAGEN FOR                    PRODUCTION OF THAPSIGARGIN

05.02.11 - GENSPERA COMPLETES $2.2 MILLION PRIVATE PLACEMENT

03.28.11 - GENSPERA ANNOUNCES FIRST PATIENT DOSED AT CANCER THERAPY
                   & RESEARCH CENTER IN ONGOING G-202 PHASE I TRIAL

03.17.11 - GENSPERA RECEIVES PATENT ON SECOND PROSTATE-TARGETING
                   ONCOLOGY DRUG

2010

11.30.10 - GENSPERA EXPANDS G-202 PHASE I CLINICAL PROGRAM

11.04.10 - GENSPERA AWARDED TWO FEDERAL GRANTS

08.17.10 - GENSPERA APPOINTS DR. BO JESPER HANSEN TO ITS BOARD OF DIRECTORS

08.10.10 - GENSPERA RECEIVES ADDITIONAL PATENT ON LEAD ONCOLOGY PRODRUG, G-202

08.03.10 - GENSPERA ACQUIRES RIGHTS TO CANCER IMAGING TECHNOLOGY

05.18.10 - SOURCE CAPITAL GROUP SPRING SMALL CAP VIRTUAL CONFERENCE

02.02.10 - GENSPERA RECEIVES PATENT ON SECOND ANTI-CANCER DRUG, G-115

01.27.10 - GENSPERA ANNOUNCES FIRST CANCER PATIENT TREATED WITH G-202
                    IN PHASE I TRIAL

2009

12.15.09 - GENSPERA RECEIVES APPROVAL TO COMMENCE G-202 PHASE I TRIAL
                    AT THE UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER

11.03.09 - GENSPERA'S COMMON STOCK COMMENCES TRADING

09.11.09 - GENSPERA RECEIVES FDA APPROVAL FOR G-202 PHASE I CANCER TRIAL